Galapagos (GLPG)
(Delayed Data from NSDQ)
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.58 USD
+0.24 (0.82%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.62 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Galapagos-Gilead Begin Phase II Study on Uveitis Candidate
by Zacks Equity Research
Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.
Illumina (ILMN) Launches VeriSeq NIPT Solution in Europe
by Zacks Equity Research
Illumina, Inc. (ILMN) recently announced the launch of a solution pertaining to its noninvasive prenatal testing (NIPT) range in Europe.
Amedisys (AMED) Poised on Strong Home Health, Risks Remain
by Zacks Equity Research
On Apr 04, we issued an updated research report on renowned home health and hospice services provider, Amedisys Inc. (AMED).
Galapagos Initiates 3 Phase II Studies for Filgotinib
by Zacks Equity Research
Galapagos NV (GLPG) announced that it has initiated three new phase II Proof-of-Concept studies evaluating its pipeline candidate filgotinib in Sjogren's syndrome, ankylosing spondylitis (AS), and psoriatic arthritis.
QIAGEN Releases Favorable GeneReader Results, Expands in NGS
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.
The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Milacron Holdings, Galapagos NV and Raymond James Financial
Can The Uptrend Continue for Galapagos (GLPG)?
by Zacks Equity Research
Investors certainly have to be happy with Galapagos NV (GLPG) and its short term performance
BioTime (BTX) Shows Strength: Stock Adds 7.1% in Session
by Zacks Equity Research
BioTime, Inc. (BTX) was above 7% in the last trading session.
Why Galapagos (GLPG) Could Be Positioned for a Surge?
by Zacks Equity Research
Galapagos NV (GLPG) is a Medial-Biomedical and Genetics company that could be an interesting play for investors.